{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:57:55Z","timestamp":1789095475295,"version":"build-2803163510"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Male osteoporosis treatment lacks robust comparisons of efficacy and safety among key medications. This network meta-analysis (NMA) aimed to systematically evaluate alendronate (ALE), risedronate (RIS), teriparatide (TER), and denosumab (DEN) in male patients, addressing this critical evidence gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA 2020 guidelines, we conducted a systematic review and NMA. Databases were searched for randomized controlled trials (RCTs) comparing these drugs in males with osteoporosis (PICOS criteria). Pairwise meta-analysis (Stata 18.0) assessed effect sizes, while NMA (R 4.3.1, gemtc and BUGSnet packages) ranked treatments for BMD changes (lumbar spine, femoral neck, total hip) and safety outcomes (adverse and serious adverse events).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2729 screened records, 12 studies were included. TER ranked highest for lumbar spine BMD improvement and overall safety (lowest adverse events). ALE showed superior femoral neck and total hip BMD gains but higher adverse event risks vs. TER. DEN improved BMD at all sites but had the poorest safety profile (highest adverse events). RIS was safest (lowest serious adverse events) but least effective for BMD enhancement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Teriparatide is the optimal choice for improving lumbar spine BMD and overall safety, while alendronate shows significant efficacy in enhancing femoral neck and hip BMD, although its safety profile is less favorable. Thus, alendronate may be more suitable for patients needing bone density improvement at these sites. Treatment choices should weigh site-specific needs against risk tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero<\/jats:uri>\n                      , identifier CRD42024599021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1579101","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:12:33Z","timestamp":1750291953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shu Jun","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu Lu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/m19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: A systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Internal Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0078-1","article-title":"A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men","volume":"12","author":"Mikyas","year":"2014","journal-title":"Appl Health Economics Health Policy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02792-0","article-title":"Health-related quality of life in men with osteoporosis: A systematic review and meta-analysis","volume":"74","author":"Hu","year":"2021","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01239-2","article-title":"Cost effectiveness analyses of interventions for osteoporosis in men: A systematic literature review","volume":"41","author":"Li","year":"2023","journal-title":"PharmacoEconomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: A comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthopaedic Surg Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00012-2","article-title":"Osteoporosis in men","volume":"10","author":"Vilaca","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","first-page":"101551","article-title":"Menopausal hormone therapy for the management of osteoporosis","volume-title":"Best Practice Res Clin Endocrinol Metab","author":"Gosset","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3810\/pgm.2010.01.2102","article-title":"Primary care use of frax: absolute fracture risk assessment in postmenopausal women and older men","volume":"122","author":"Siris","year":"2010","journal-title":"Postgrad Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11657-023-01317-8","article-title":"Effects of exercise on bone mineral density in middle-aged and older men: A comprehensive meta-analysis","volume":"18","author":"Lu","year":"2023","journal-title":"Arch Osteoporosis"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128310838240820065324","article-title":"Alendronate for effective treatment of male osteoporosis: an insight","volume-title":"Curr Pharmaceutical Des","author":"Al Lawati","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/b978-0-12-407691-4.00001-0","article-title":"Alendronate sodium","volume":"38","author":"Ananchenko","year":"2013","journal-title":"Profiles Drug Substances Excipients Related Method"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4238\/gmr16019485","article-title":"Effects of alendronate on osteoporosis treatment and levels of related cytokines","volume":"16","author":"Liu","year":"2017","journal-title":"Genet Mol Res: GMR"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115407","article-title":"History of risedronate","volume":"137","author":"McClung","year":"2020","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00002512-199813010-00008","article-title":"Risedronate","volume":"13","author":"Goa","year":"1998","journal-title":"Drugs Aging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2017.10.019","article-title":"Update on osteoporosis treatment","volume":"150","author":"Nogu\u00e9s","year":"2018","journal-title":"Med Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052218-020620","article-title":"New frontiers in osteoporosis therapy","volume":"71","author":"Cheng","year":"2020","journal-title":"Annu Rev Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(04)90128-2","article-title":"Teriparatide: a review","volume":"26","author":"Quattrocchi","year":"2004","journal-title":"Clin Ther"},{"key":"B19","article-title":"Teriparatide: a review of its use in osteoporosis","volume-title":"Drugs","author":"Blick","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070171","article-title":"Teriparatide in the treatment of osteoporosis","volume":"65","author":"Stroup","year":"","journal-title":"Am J Health Syst Pharm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10\u2002years later: A narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00000441-199701000-00004","article-title":"Bisphosphonate therapy","volume":"313","author":"Licata","year":"1997","journal-title":"Am J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.68.11.945","article-title":"Role of alendronate and risedronate in preventing and treating osteoporosis","volume":"68","author":"Peters","year":"2001","journal-title":"Cleveland Clin J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet (London England)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202105_25838","article-title":"Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment","volume":"25","author":"Ta\u0144ski","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the data study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet (London England)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the prisma-dta statement","volume":"319","author":"McInnes","year":"2018","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s43390-023-00646-5","article-title":"Discrepancy between dxa and ct-based assessment of spine bone mineral density","volume":"11","author":"Davidson","year":"2023","journal-title":"Spine Deform"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/08968608221146867","article-title":"Differences in prevalence of reduced and low bone mineral density between lumbar spine and femoral neck in peritoneal dialysis patients using dual-energy X-ray absorptiometry (Dxa)","volume":"43","author":"Davenport","year":"2023","journal-title":"Peritoneal Dialysis International: J Int Soc Peritoneal Dialysis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00744-w","article-title":"Effects of different types of exercise on bone mineral density in postmenopausal women: A systematic review and meta-analysis","volume":"107","author":"Kemmler","year":"2020","journal-title":"Calcified Tissue Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: A meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.crtox.2020.06.001","article-title":"Development of an adverse drug event network to predict drug toxicity","volume":"1","author":"Wu","year":"2020","journal-title":"Curr Res Toxicol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e069722","DOI":"10.1136\/bmj-2022-069722","article-title":"Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis","volume":"378","author":"Pereira","year":"2022","journal-title":"BMJ (Clin Res Ed)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1446","article-title":"Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis","volume":"374","author":"Cashin","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9001","article-title":"Biportal endoscopic decompression vs. Microscopic decompression for lumbar canal stenosis: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"Exp Ther Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.1987","article-title":"The consort statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"Jama"},{"key":"B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"Bugsnet: an R package to facilitate the conduct and reporting of bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Method"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.08.042","article-title":"Epidemiological, methodological, and statistical characteristics of network meta-analysis in anaesthesia: A systematic review","volume":"130","author":"Sehmbi","year":"2023","journal-title":"Br J Anaesthesia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synthesis Methods"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcified Tissue Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1879-3","article-title":"Alendronate for osteoporosis in men with androgen-repleted hypogonadism","volume":"16","author":"Shimon","year":"2005","journal-title":"Osteoporosis International: J Established As Result Cooperation Between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (Direct)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"New Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcified Tissue Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v20i10.26","article-title":"Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic chinese patients","volume":"20","author":"Qi","year":"2021","journal-title":"Trop J Pharm Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [Human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0136-9","article-title":"The effects of weekly alendronate therapy in Taiwanese males with osteoporosis","volume":"28","author":"Hwang","year":"2010","journal-title":"J Bone Mineral Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Mineral Res: Off J Am Soc Bone Mineral Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporosis International: J Established As Result Cooperation Between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clin Drug Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: A systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: A systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatrics Soc"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0128032","DOI":"10.1371\/journal.pone.0128032","article-title":"Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: A network meta-analysis","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1579101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:12:35Z","timestamp":1750291955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1579101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":62,"alternative-id":["10.3389\/fendo.2025.1579101"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1579101","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"article-number":"1579101"}}